We believe that the use of cauterization in patients with anterior epistaxis in the absence of acute bleeding should be discouraged because it does not address the underlying cause and because it may even worsen the condition by extending the degree of mucosal disruption. Th is is especially true in patients who are receiving anticoagulation therapy. Th erefore, we conducted a study to determine if the use of a nasal saline gel as monotherapy would be an eff ective alternative to invasive measures in treating recurrent epistaxis in anticoagulated patients. Our study group consisted of 74 patients-43 men and 31 women (mean age: 64.4 yr)-who had been seen in our department over an 18-month period and whose bleeding had originated in the anterior portion of the nasal vault. Most patients had been experiencing epistaxis for at least 6 months. Patients were given the saline nasal gel and taught to gently apply it to the mucosa of the anterior nasal vault with a cotton-tipped applicator at the fi rst sign of recurrent bleeding. Patients were then followed up periodically over the next 3 months. Among the 74 patients, 69 (93.2%) had experienced a cessation of their epistaxis at 3 months. Th e results of our study suggest that this simple, painless technique has considerable value as a treatment option in this cohort of patients.
Introduction
Th e vast majority of epistaxis cases occur at an anterior site of the nose. Th e predisposing factor in most of these cases is dehydration of the anterior nasal mucosa. 1 In clinical practice, anticoagulation signifi cantly increases the prevalence of this condition and its recurrence. As more patients are being prescribed anticoagulation therapy for various cardiac and vascular conditions, the incidence of associated epistaxis is expected to rise.
Antiseptic creams have been studied as a sole therapeutic option for patients with anterior epistaxis. 2 We sought to extend these previous investigations to include the anticoagulated population and to study the role of a nasal saline gel as a means of avoiding invasive measures such as cauterization. 3 We believe that the use of cauterization in patients with anterior epistaxis in the absence of acute bleeding should be discouraged because it does not address the underlying cause and because it may even worsen the condition by extending the degree of mucosal disruption. Th e administration of anticoagulation in patients with disrupted mucosa further raises the risk of epistaxis. Th erefore, any treatment strategy that avoids the use of cauterization and other invasive modalities may be benefi cial for anticoagulated patients.
With that in mind, we conducted a study to determine if the use of a nasal saline gel as monotherapy would be eff ective in treating chronic epistaxis in anticoagulated patients.
Patients and methods
Our study group was drawn from among all anticoagulated patients with chronic epistaxis who had been 
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population is advisable in the nonacute setting because any additional mucosal disruption will likely predispose to additional episodes of epistaxis if the underlying cause is not addressed. Th is was demonstrated in a previous study of antiseptic creams by Murthy et al. 3 Our fi ndings mirror this previous work, which suggested that in the absence of nasal vestibulitis, the emollient properties of the antiseptic cream may reduce the local dehydration around the surface of the blood vessels and thereby reduce their predisposition to respiratory shearing trauma. Whether the use of a nasal saline gel off ers any additional benefi ts over that of an antiseptic cream is probably not clinically signifi cant at this time, although future studies might address this issue.
We were unable to reach any defi nitive conclusions about the eff ects of seasonal changes on epistaxis in our population because recurrences were seen evenly throughout the course of the year. Moreover, although we did not seek to study or record the eff ects of additional hydration procedures (e.g., home humidifi cation and local saline lavage), we believe that these measures would likely have had an additive eff ect with regard to promoting hemostasis.
In conclusion, the nasal saline gel appeared to be an eff ective therapeutic agent in our cohort, allowing for a exclusion criteria (table 1) . Informed consent was obtained from all patients.
In addition to demographic data, information was collected on the duration of epistaxis, the most recent international normalized ratio (INR), and the reason for anticoagulation. Most patients had been experiencing epistaxis for at least 6 months, and the group's mean INR was 2.40. About half of the patients had been receiving anticoagulation therapy for a cardiac condition, and the rest for either peripheral vascular disease or pulmonary embolism (table 2). All patients underwent a detailed direct headlight and endoscopic examination with a 0° and 30° endoscope. Care was taken to identify any additional sites of bleeding other than the anterior nasal area.
All study patients were given a 0.5-oz (14.2-g) tube of saline nasal gel (Ayr Saline Nasal Gel; B.F. Ascher & Co.; Lenexa, Kans.), along with a list of pharmacies that stocked the gel. Patients then received instructions on how to put a generous portion of gel onto a cottontipped applicator and gently apply it to the mucosa of the anterior nasal vault. Patients were given a form to fi ll out on which they could detail any subsequent episodes of epistaxis over the next 3 months, and they were also given contact information in the event of persistent or severe bleeding.
Th ereaft er, all patients were either seen in person or contacted by telephone at 1 week, 1 month, and 3 months to determine the number of recurrent bleeding episodes.
Results
Among the 74 patients, 69 (93.2%) had experienced a cessation of their epistaxis at 3 months. Th e remaining 5 patients required cauterization in the offi ce or operating room. Additional treatment was required for 3 of the 5 patients, including 1 man who underwent 5 additional cauterizations before his epistaxis ceased.
Discussion
Th e goal of this preliminary, uncontrolled study was to evaluate the effi cacy of a nasal saline gel in preventing recurrent episodes in anticoagulated patients with chronic anterior epistaxis. As the population ages, the size of this cohort of patients will likely increase. Th e results of our study suggest that this simple, painless technique has considerable value as a treatment option.
As mentioned, the avoidance of cauterization in this decrease in the use of nasal cauterization. Th is treatment is a simple, painless, and cost-eff ective means of managing chronic anterior epistaxis in anticoagulated patients. Our patients were pleased with the comfort provided by the saline gel, which might have been attributable in part to the aloe vera that was used in its formulation. Th e nasal saline gel may serve as a single-agent management strategy for recurrent anterior epistaxis or in conjunction with nasal saline irrigation to hydrate the anterior nasal mucosa.
